Daily Market Reports | May 05 2026
This story features 29METALS LIMITED, and other companies.
For more info SHARE ANALYSIS: 29M
The company is included in ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
29M A11 ANZ AR1 ARX AWJ BET BGL BMN BOT BUB CMA CMM COL CYG CYL DUG FLT GEM GNC HPG KCN LMG LTR MLX NMG OMA RMD (2) RMS SCG SGLLV SKC STM TEA TLX WGX
29M 29METALS LIMITED
Copper – Overnight Price: $0.23
Canaccord Genuity rates ((29M)) as Upgrade to Hold from Sell (3) –
Canaccord Genuity upgrades 29Metals to Hold from Sell with a $0.25 price target following a first-quarter update.
Copper production was stronger than expected, although zinc output was materially constrained by restricted access at the Xantho Extended orebody.
Net cash improved following the recent capital raising, but higher operating costs weighed on the quarter.
Future value is tied to securing regulatory approval for the TSF3 tailings facility, which is required before operations can restart at Capricorn Copper.
Forecasts have been revised higher following the update, although the broker views the stock as trading close to fair value.
This report was published on May 4, 2026.
Target price is $0.25 Current Price is $0.23 Difference: $0.02
If 29M meets the Canaccord Genuity target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $0.34, suggesting upside of 46.4%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 4.79.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -3.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.93.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 0.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 57.5.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
A11 ATLANTIC LITHIUM LIMITED.
New Battery Elements – Overnight Price: $0.29
Canaccord Genuity rates ((A11)) as Speculative Buy (1) –
Canaccord Genuity reiterates its Speculative Buy rating and 43p target price for Atlantic Lithium following the release of its March quarter activities report.
The broker notes the company remains comfortably funded to reach a Final Investment Decision (FID) at its Ewoyaa project, supported by a healthy cash balance of $13.9m at the end of March following a recent capital raise.
Project technical committees are currently evaluating alternative development pathways to optimise initial project scale or secondary product quality through a potential flotation stage.
While joint venture partner Elevra Lithium ((ELV)) has publicly expressed a desire to amend the existing funding structure to be more equitable, Canaccord Genuity believes a strong lithium market remains supportive of traditional debt or equity alternatives.
The broker’s base case assumes Ewoyaa receives construction approval by the end of 2026, with initial production targeted for late 2028.
This report was published on May 3, 2026.
Current Price is $0.29. Target price not assessed.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ANZ ANZ GROUP HOLDINGS LIMITED
Banks – Overnight Price: $36.29
Jarden rates ((ANZ)) as Overweight (2) –
Jarden maintains an Overweight rating for ANZ Bank and lifts the target price to $35.50 from $35.00 following a strong first-half result.
First-half core profit jumped 51% sequentially, driven by disciplined cost control, a -22% reduction in operating expenses, and resilient net interest margins amid broader macroeconomic uncertainties tied to the Middle East conflict.
The broker notes management is successfully executing the first phase of its 2030 strategy, recently upgrading gross cost-saving targets to $875m while progressing the Suncorp Bank integration.
Reflecting improved asset quality and lower deposit pricing competition, Jarden has upgraded cash earnings forecasts across the FY26-FY28 period, though near-term EPS estimates edge slightly lower to 250.8c from 252.7c for FY26.
The report concludes the bank remains well-capitalised to navigate future economic headwinds, providing ongoing support for dividend growth and long-term franchise expansion.
This report was published on May 1, 2026.
Target price is $35.50 Current Price is $36.29 Difference: minus $0.79 (current price is over target).
If ANZ meets the Jarden target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $35.18, suggesting downside of -3.1%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 167.00 cents and EPS of 250.80 cents.
At the last closing share price the estimated dividend yield is 4.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.47.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 248.2, implying annual growth of 25.2%.
Current consensus DPS estimate is 166.8, implying a prospective dividend yield of 4.6%.
Current consensus EPS estimate suggests the PER is 14.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 169.00 cents and EPS of 270.80 cents.
At the last closing share price the estimated dividend yield is 4.66%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.40.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 255.1, implying annual growth of 2.8%.
Current consensus DPS estimate is 173.8, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 14.2.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AR1 AUSTRAL RESOURCES AUSTRALIA LIMITED
Copper – Overnight Price: $0.08
Shaw and Partners rates ((AR1)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Austral Resources Australia with a $0.42 target price following the release of the March quarter report.
The broker highlights the recent $55.9m acquisition of Lady Loretta from Glencore finalises a three-pillar consolidation strategy in northwest Queensland, leaving the producer debt-free with $83m in net cash.
With mining operations at Anthill now complete, the focus shifts to processing remaining stockpiles while a two-year refurbishment of the Rocklands concentrator aims to unlock 50ktpa of copper production by late 2027.
Commentary notes the business is building a compelling growth story against a favourable macroeconomic backdrop of robust copper prices and rising critical minerals demand.
The report outlines an expected return to profitability by 2027, driven by the transformation of Rocklands into a regional processing hub catering to both internal and third-party ore.
This report was published on May 4, 2026.
Target price is $0.42 Current Price is $0.08 Difference: $0.343
If AR1 meets the Shaw and Partners target it will return approximately 445% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 10.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 0.71.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.81.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ARX AROA BIOSURGERY LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.64
Canaccord Genuity rates ((ARX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Aroa Biosurgery, upgrading its target price to $1.35 from $1.16 after a strong FY26 trading update exceeded management’s expectations.
Revenue of NZ$104m and underlying EBITDA between NZ$11m and NZ$12m both outperformed guidance, driven by dramatic growth acceleration for the Myriad product in the fourth quarter.
The report attributes this outperformance to disciplined sales execution and strong clinical resonance from the Mastrr study, particularly within the US soft tissue repair market.
Looking ahead, recent regulatory changes to skin-substitute reimbursement are expected to pivot patients toward hospital outpatient settings, a shift ideally suited to the company’s existing infrastructure, commentary suggests.
Management expects the upcoming Symphony launch into chronic wound care to provide a sustainable catalyst for further decoupling stock performance from broader sector trends through FY28.
This report was published on May 3, 2026.
Target price is $1.35 Current Price is $0.64 Difference: $0.71
If ARX meets the Canaccord Genuity target it will return approximately 111% (excluding dividends, fees and charges).
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AWJ AURIC MINING LIMITED
Gold & Silver – Overnight Price: $0.34
Taylor Collison rates ((AWJ)) as Speculative Buy (1) –
The March quarter was a defining one for Auric Mining, Taylor Collison suggests, and one that sets the company up for the next stage of progression.
On the production front, Munda Starter Pit outperformed the original Reserve estimate by 46%, with gold sold at $7,178/oz that takes the cash balance to $46m at quarter-end against a debt-free balance sheet.
The grade and gold production outperformance materially de-risks the broader Munda orebody, the broker suggests, and supports re-estimation of resources to underpin a much larger Main Pit than the current circa 140koz.
The report concludes Auric’s operational outperformance has fundamentally transformed both the balance sheet and the company, setting Auric up well for the next stage of growth. Speculative Buy retained, target 73c.
This report was published on May 4, 2026.
Target price is $0.73 Current Price is $0.34 Difference: $0.39
If AWJ meets the Taylor Collison target it will return approximately 115% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BET BETMAKERS TECHNOLOGY GROUP LIMITED
Gaming – Overnight Price: $0.17
Canaccord Genuity rates ((BET)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Betmakers Technology with a steady $0.24 target price following a solid third-quarter result that validates the company’s operational turnaround.
Adjusted EBITDA margins improved to 15% on a 67% gross margin, with annualised Adjusted EBITDA now pacing near $14m.
The broker notes the successful launch of the CrownBet wagering brand as a critical milestone, confirming the capability of the Apollo platform and its market-leading presence.
Tight cost management saw the employee cost base remain largely unchanged year-on-year, while the acquisition of LVDC is expected to add roughly $4.5m in annual revenue.
Management continues to target consistent free cash flow generation as the business scales, supported by renewed commercial terms with PENN and upcoming regional launches for stake.com.
This report was published on May 3, 2026.
Target price is $0.24 Current Price is $0.17 Difference: $0.07
If BET meets the Canaccord Genuity target it will return approximately 41% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BGL BELLEVUE GOLD LIMITED
Gold & Silver – Overnight Price: $1.55
Canaccord Genuity rates ((BGL)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating for Bellevue Gold with a target price of $2.35 following what it views as a strong March quarter performance.
The company reported gold production of 41koz, representing a 27% sequential increase and a significant beat against market expectations.
Operations trended positively as the mill reached a steady throughput of 283kt, with milled grades rising 27% to 4.7g/t as mining transitioned into higher-grade zones.
While all-in sustaining costs (AISC) of $2,578/oz were slightly above the broker’s estimate, they fell -14% quarter-on-quarter due to these improved grades.
Management remains well-positioned to meet the midpoint of its FY26 guidance, while the broker highlights FY27 screens attractively with an expected production increase to 163koz.
This report was published on May 3, 2026.
Target price is $2.35 Current Price is $1.55 Difference: $0.8
If BGL meets the Canaccord Genuity target it will return approximately 52% (excluding dividends, fees and charges).
Current consensus price target is $2.13, suggesting upside of 37.6%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 5.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 26.7.
Forecast for FY27:
Current consensus EPS estimate is 22.3, implying annual growth of 284.5%.
Current consensus DPS estimate is 2.5, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 7.0.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BMN BANNERMAN ENERGY LIMITED
Uranium – Overnight Price: $4.08
Canaccord Genuity rates ((BMN)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating for Bannerman Energy with an unchanged $5.80 target price following a quarter labeled as of significant operational and strategic progress.
The company is advancing site preparations at its Etango uranium project in Namibia, with bulk earthworks now 66.5% complete and critical infrastructure, including water supply pipelines and power agreements, ahead of schedule.
A major strategic milestone was reached with the CNNC transaction, which remains on track for mid-2026 completion and is expected to leave the project fully funded to first production via a US$294.5m subscription.
The broker highlights Bannerman Energy will retain majority control and full operating oversight, keeping approximately 40% of life-of-mine production for independent sale to capitalise on sustained utility interest.
With a debt-free construction pathway and high leverage to U3O8 prices, the broker views the company as providing one of the cleanest exposures to the global nuclear energy thematic.
This report was published on May 3, 2026.
Target price is $5.80 Current Price is $4.08 Difference: $1.72
If BMN meets the Canaccord Genuity target it will return approximately 42% (excluding dividends, fees and charges).
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BOT BOTANIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.03
Canaccord Genuity rates ((BOT)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Botanix Pharmaceuticals with a steady $0.14 target price following the release of its third-quarter FY26 results.
The company reported script numbers and revenue slightly ahead of updated forecasts, generating US$26.4m in gross revenue, albeit offset somewhat by unfavourable foreign exchange movements.
The broker notes the launch of its primary product has been softer than initially anticipated, but Botanix is demonstrating strong patient retention driven by ease of onboarding and high refill rates.
Looking ahead, Canaccord Genuity expects a moderate uptick in fourth-quarter scripts as the US enters its summer period, forecasting 32,592 scripts (a 22% sequential increase) and an improving gross-to-net yield.
Cash flows are also expected to benefit over the coming 12–18 months following the successful renegotiation of active pharmaceutical ingredient (API) supply agreements.
This report was published on May 3, 2026.
Target price is $0.14 Current Price is $0.03 Difference: $0.114
If BOT meets the Canaccord Genuity target it will return approximately 438% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BUB BUBS AUSTRALIA LIMITED
Dairy – Overnight Price: $0.10
Shaw and Partners rates ((BUB)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Bubs Australia, trimming its target price to $0.16 from $0.18, following the release of the third-quarter activities report.
Revenue rose 10% to $25.5m over the corresponding period, underpinned by a 43% increase in US sales, which remains the group’s largest revenue contributor.
The broker notes trading conditions remain challenging in Australia, China, and rest-of-world markets due to consumer spending pressures and inventory constraints.
Shaw and Partners has lowered its FY26 revenue forecast by -7.5% to $112.4m, noting the company’s full-year guidance of $120-$125m looks increasingly challenging to meet.
Despite these near-term headwinds, Shaw maintains the underlying investment thesis remains intact, supported by a 98% increase in US store distribution and an impending, potentially catalytic, FDA approval.
This report was published on May 4, 2026.
Target price is $0.16 Current Price is $0.10 Difference: $0.06
If BUB meets the Shaw and Partners target it will return approximately 60% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 33.33.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 50.00.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CMA CARMA LIMITED
Automobiles & Components – Overnight Price: $0.73
Canaccord Genuity rates ((CMA)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Carma with a steady $3.50 target price following a third-quarter performance that met expectations and solidified the company’s platform for future growth.
Revenue surged 94% year-on-year to $29m, driven by robust performance in the Wholesale division which saw units delivered skyrocket 237% year-on-year.
The broker notes that Carma successfully cleared excess pre-reconditioned inventory accumulated over the holiday period, leading to a substantial step-up in cars listed online.
This inventory build is crucial, as the broker highlights it serves as a leading indicator for revenue growth.
With $48m in available liquidity, the report highlights Carma maintains approximately 18 months of cash runway, positioning it well to achieve management’s fourth-quarter revenue target of roughly $48m and scale operations materially into FY27.
This report was published on May 3, 2026.
Target price is $3.50 Current Price is $0.73 Difference: $2.765
If CMA meets the Canaccord Genuity target it will return approximately 376% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CMM CAPRICORN METALS LIMITED
Gold & Silver – Overnight Price: $11.90
Canaccord Genuity rates ((CMM)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Capricorn Metals while lowering the target price to $19.85 from $20.10 following an in-line March quarter production result.
The broker reduced its valuation after pushing assumed first gold production at the Mt Gibson project out by three months to the December quarter of 2027, as final environmental permitting assessments remain in progress.
Operations at the flagship Karlawinda mine remain steady ahead of an upcoming expansion, with management actively monitoring broader Australian diesel supply chain vulnerabilities despite experiencing no direct fuel interruptions.
The company delivered 30.4koz of gold at an all-in sustaining cost of $1,617/oz, generating strong free cash flow and boosting the balance sheet to $508m in cash and bullion.
With operations tracking toward the upper end of full-year guidance, the broker views recent underground drill results at Lexington as offering further upside to the base case mine plan.
This report was published on May 3, 2026.
Target price is $19.85 Current Price is $11.90 Difference: $7.95
If CMM meets the Canaccord Genuity target it will return approximately 67% (excluding dividends, fees and charges).
Current consensus price target is $18.70, suggesting upside of 57.1%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 70.4, implying annual growth of 89.9%.
Current consensus DPS estimate is 11.0, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 16.9.
Forecast for FY27:
Current consensus EPS estimate is 97.2, implying annual growth of 38.1%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 12.2.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
COL COLES GROUP LIMITED
Food, Beverages & Tobacco – Overnight Price: $22.02
Jarden rates ((COL)) as Downgrade to Neutral from Overweight (3) –
Jarden has downgraded Coles Group to Neutral from Overweight following a period of relative share price outperformance, while concurrently lifting its target price to $22.60 from $21.60.
Commentary states the third-quarter update revealed a robust performance in food, with sales growing 4% supported by disciplined cost control, easing theft, and strong online momentum.
Conversely, the liquor division underperformed significantly, exiting the period with sales down more than -5% as lower foot traffic and heightened discounting weighed on margins.
Jarden has maintained its near-term earnings forecasts but modestly trimmed outer-year expectations, noting the supermarket giant’s discount to rival Woolworths ((WOW)) has narrowed back to historical averages.
Ultimately, the broker believes Coles is well-positioned structurally, but sees more compelling near-term upside elsewhere in the consumer discretionary sector.
This report was published on May 1, 2026.
Target price is $22.60 Current Price is $22.02 Difference: $0.58
If COL meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $23.81, suggesting upside of 8.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 78.00 cents and EPS of 93.40 cents.
At the last closing share price the estimated dividend yield is 3.54%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.58.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 92.6, implying annual growth of 14.7%.
Current consensus DPS estimate is 78.2, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 23.8.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 85.00 cents and EPS of 102.50 cents.
At the last closing share price the estimated dividend yield is 3.86%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.48.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 102.1, implying annual growth of 10.3%.
Current consensus DPS estimate is 85.2, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 21.6.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CYG COVENTRY GROUP LIMITED
Hardware & Equipment – Overnight Price: $0.38
Taylor Collison rates ((CYG)) as Hold (3) –
Coventry Group operates two distinct businesses, Taylor Collison points out: Fluid Systems – a distributor and engineer of industrial products and services across hydraulic, pneumatic and refueling markets — and Trade Distribution – a distributor of fasteners across A&NZ.
The two divisions have minimal strategic overlap, generate standalone profits and cash flow, and exhibit no material synergies. As such, the broker sees meaningful potential for a divestment strategy to unlock shareholder value.
While the divisions, when separated, are more valuable than the current share price implies, management must rectify the cash drain to allow the breakup thesis to still be achieved, Taylor Collison believes.
Hold retained, no target price offered.
This report was published on May 4, 2026.
Current Price is $0.38. Target price not assessed.
The company’s fiscal year ends in June.
Forecast for FY26:
Taylor Collison forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 13.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 2.81.
Forecast for FY27:
Taylor Collison forecasts a full year FY27 dividend of 0.00 cents and EPS of 5.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.17.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CYL CATALYST METALS LIMITED
Gold & Silver – Overnight Price: $5.40
Canaccord Genuity rates ((CYL)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Catalyst Metals, lowering the price target to $14.75 from $15.15 following a “weak” March quarter production update.
Group production missed expectations at 26koz due to lower milled grades and plant downtime, while all-in sustaining costs rose to $2,853/oz.
The report notes fiscal year 2026 all-in sustaining cost guidance increased 17% to a midpoint of $2,850/oz to reflect processing plant downtime and inflationary pressures.
Operational momentum should improve as the K2 underground mine ramps up this quarter and Trident transitions to underground development following the conclusion of open pit mining, commentary suggests.
Despite near-term cost headwinds, Canaccord Genuity concludes the portfolio remains well-positioned for growth into 2027 through the development of the Old Highway project and steady-state contributions from K2.
This report was published on May 4, 2026.
Target price is $14.75 Current Price is $5.40 Difference: $9.35
If CYL meets the Canaccord Genuity target it will return approximately 173% (excluding dividends, fees and charges).
Current consensus price target is $13.16, suggesting upside of 143.7%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 72.3, implying annual growth of 56.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 7.5.
Forecast for FY27:
Current consensus EPS estimate is 138.8, implying annual growth of 92.0%.
Current consensus DPS estimate is 4.7, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 3.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
DUG DUG TECHNOLOGY LIMITED
Cloud services – Overnight Price: $2.38
Canaccord Genuity rates ((DUG)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Dug Technology with an unchanged target price of $3.00, following what is labeled a robust third-quarter performance.
Consistent services revenue and a step-up in software contribution drove EBITDA margins near 35% on a last-six-months basis, underscoring the benefits of scale and growing recurring revenue.
The closing cash balance of $24.4m stood out as a highlight, bolstered by strong underlying free cash flow and the receipt of annual upfront EPIC payments.
The broker views the recent launch of the Elastic MP-FWI product and regional expansion into Brazil and the Middle East as key catalysts for future contract awards, particularly amid a high oil price environment.
Canaccord Genuity has made minor upward revisions to its near and medium-term earnings forecasts, noting the company is tracking comfortably towards FY26 and FY27 targets.
This report was published on May 4, 2026.
Target price is $3.00 Current Price is $2.38 Difference: $0.62
If DUG meets the Canaccord Genuity target it will return approximately 26% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
FLT FLIGHT CENTRE TRAVEL GROUP LIMITED
Travel, Leisure & Tourism – Overnight Price: $10.16
Canaccord Genuity rates ((FLT)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Flight Centre Travel but lowers its target price to $14.60 from $16.00.
The broker has trimmed its earnings forecasts for the FY26 and FY27 periods, reflecting weaker international travel demand stemming from ongoing conflict in the Middle East.
Recent IATA data indicates a sharp 60.8% decline in demand for Middle East carriers, which is expected to negatively impact Flight Centre’s performance heading into the critical May/June booking window.
Despite these external macroeconomic pressures, Canaccord Genuity notes underlying improvements within the Corporate division and expects activity to normalise once geopolitical tensions subside.
The broker cautions against overly optimistic market expectations of a “hockey stick” recovery in FY27, warning sub-par economic conditions and the accounting treatment of the Rewards 360 program will likely temper growth.
The broker views the stock’s current valuation as offering strong fundamental support despite the likelihood of near-term negative news flow.
This report was published on May 3, 2026.
Target price is $14.60 Current Price is $10.16 Difference: $4.44
If FLT meets the Canaccord Genuity target it will return approximately 44% (excluding dividends, fees and charges).
Current consensus price target is $16.65, suggesting upside of 63.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 42.00 cents and EPS of 104.00 cents.
At the last closing share price the estimated dividend yield is 4.13%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.77.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 103.0, implying annual growth of 107.5%.
Current consensus DPS estimate is 43.8, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 9.9.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 44.00 cents and EPS of 116.00 cents.
At the last closing share price the estimated dividend yield is 4.33%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.76.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 122.1, implying annual growth of 18.5%.
Current consensus DPS estimate is 49.7, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 8.3.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GEM G8 EDUCATION LIMITED
Childcare – Overnight Price: $0.17
Canaccord Genuity rates ((GEM)) as Hold (3) –
Canaccord Genuity maintains its Hold rating for G8 Education and has significantly reduced its target price to $0.27 from $0.49 following a “weak” AGM trading update.
Spot occupancy as of April 24 was reported at 56.4%, representing a -700bps decline compared to the previous corresponding period, primarily due to a tough operating environment and a lack of progress in underperforming centres.
The broker downgraded its 2026 EBIT estimate by -31%, reflecting lower occupancy rates and a reduction in net centres as the company pursues centre suspensions to save costs.
While G8 Education is implementing cost-out initiatives such as headcount reduction and procurement savings, the broker notes a heightened risk profile with a projected 2026 fixed cover charge ratio of less than 1.5x.
Despite these challenges, the broker believes the current valuation is suppressed by poor consumer macroeconomic sentiment, expecting a crucial earnings recovery in 2027 to drive leverage back down.
This report was published on May 3, 2026.
Target price is $0.27 Current Price is $0.17 Difference: $0.1
If GEM meets the Canaccord Genuity target it will return approximately 59% (excluding dividends, fees and charges).
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GNC GRAINCORP LIMITED
Agriculture – Overnight Price: $6.13
Jarden rates ((GNC)) as Initiation of coverage with Underweight (4) –
Jarden initiates coverage on GrainCorp with an Underweight rating and a $6.00 target price, citing a softer outlook for the upcoming financial year not currently captured by consensus estimates.
The broker forecasts an underlying net profit of just $29.3m for FY26 — well below guidance parameters — largely driven by heavy expenditure tied to its Enterprise Resource Planning program.
Looking to FY27, an increasingly dry outlook and the potential development of an El Nino weather pattern pose significant volume risks for the Agribusiness segment, while lower global canola crush margins could similarly pressure the Nutrition & Energy division.
Jarden suggests management’s “through-the-cycle” EBITDA estimate of $320m may be overly optimistic when adjusted for historical performance patterns.
The broker notes the company’s strong asset backing, healthy balance sheet holding $321m in core net cash, and a 4.4% fully franked dividend yield provide valuation support near current trading levels.
This report was published on May 3, 2026.
Target price is $6.00 Current Price is $6.13 Difference: minus $0.13 (current price is over target).
If GNC meets the Jarden target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $6.89, suggesting upside of 12.4%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 27.60 cents and EPS of 13.40 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 45.75.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.5, implying annual growth of -9.1%.
Current consensus DPS estimate is 26.3, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 37.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 27.30 cents and EPS of 14.80 cents.
At the last closing share price the estimated dividend yield is 4.45%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 41.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 23.3, implying annual growth of 41.2%.
Current consensus DPS estimate is 27.0, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 26.3.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
HPG HIPAGES GROUP HOLDINGS LIMITED
Online media & mobile platforms – Overnight Price: $0.76
Canaccord Genuity rates ((HPG)) as Buy (1) –
hipages Group remains a Buy for Canaccord Genuity with an unchanged $1.75 target price following what has been perceived as a positive investor day update.
Management maintained FY26 revenue guidance between $90m and $91m and reiterated a long-term Cash EBIT margin target of 30%.
The broker observed usage of job management features surged to 21% of subscription tradies in March 2026, helping drive a 7.5ppt increase in retention rates.
Strategic progress includes the 51% acquisition of VIZ Insurance and the announcement of a 10% on-market share buy-back.
Integration of AI via a ChatGPT-powered assistant has improved lead conversion to 46% for tradies, reinforcing the platform’s transition to a comprehensive service provider, the report concludes.
This report was published on May 4, 2026.
Target price is $1.75 Current Price is $0.76 Difference: $0.995
If HPG meets the Canaccord Genuity target it will return approximately 132% (excluding dividends, fees and charges).
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
KCN KINGSGATE CONSOLIDATED LIMITED
Gold & Silver – Overnight Price: $6.11
Canaccord Genuity rates ((KCN)) as Buy (1) –
Kingsgate Consolidated remains a Buy for Canaccord Genuity with an unchanged $10.30 price target following a strong March quarter production beat at its Chatree operation.
Gold and silver production exceeded expectations due to higher recoveries, while all-in sustaining costs reached US$2,201/oz despite rising diesel prices.
The report notes net cash improved sequentially to $129m, positioning the company well to fund potential internal growth or future dividends.
Canaccord Genuity reduced FY26 and FY27 EBITDA estimates by -6%-7% to account for higher near-term unit mining costs.
The report concludes management remains well-placed to achieve production guidance, with improving grades expected to support roughly 20% production growth through FY27.
This report was published on May 4, 2026.
Target price is $10.30 Current Price is $6.11 Difference: $4.19
If KCN meets the Canaccord Genuity target it will return approximately 69% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LMG LATROBE MAGNESIUM LIMITED
Industrial Metals – Overnight Price: $0.02
Shaw and Partners rates ((LMG)) as Initiation of coverage with Buy (1) –
Shaw and Partners maintains a Buy rating on Latrobe Magnesium with a $0.06 price target following March quarter progress at the demonstration plant.
The company achieved first sustained production and commercial sales, marking an important step toward commercialisation.
Operations are temporarily paused to support the next development phase, with first magnesium metal production targeted as the project scales.
Future valuation is tied to successful execution of the staged expansion, with the broker highlighting Latrobe’s strategic position as a potential significant magnesium producer outside China and Russia.
This report was published on May 4, 2026.
Target price is $0.06 Current Price is $0.02 Difference: $0.043
If LMG meets the Shaw and Partners target it will return approximately 253% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LTR LIONTOWN LIMITED
New Battery Elements – Overnight Price: $2.42
Canaccord Genuity rates ((LTR)) as Buy (1) –
Canaccord Genuity reiterates a Buy rating for Liontown with an unchanged $2.85 target price following stronger than expected March quarter volumes at Kathleen Valley.
Spodumene concentrate production reached 96kt as the underground operation achieved a 1.5Mtpa run rate ahead of schedule, although increased grade variability resulted in a -9% sequential decline.
Revenue of $197m remained steady as higher sales volumes effectively balanced lower average prices driven by contract lags.
A potential expansion to 4Mtpa remains under study with a final investment decision targeted for Q1 FY27, supported by a transition to 100% underground feed.
This report was published on May 4, 2026.
Target price is $2.85 Current Price is $2.42 Difference: $0.43
If LTR meets the Canaccord Genuity target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $2.23, suggesting downside of -7.9%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 2.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 121.0.
Forecast for FY27:
Current consensus EPS estimate is 20.3, implying annual growth of 915.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.9.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MLX METALS X LIMITED
Tin – Overnight Price: $1.42
Canaccord Genuity rates ((MLX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Metals X and raises the target price to $1.55 from $1.50 following a stronger-than-expected March quarter report.
The broker highlights a broad beat across production, costs, and earnings, driven largely by a 20% jump in imputed tin pricing to $69,726/t.
This more than offset a 13% quarter-on-quarter drop in tin production to 2.9kt, which was constrained by lower grades and recoveries tied to mine sequencing.
The company’s cash position grew 22% to $359m, and it recently announced a -$17m strategic investment in Stellar Resources ((SRZ)) to explore synergies with its nearby Heemskirk Tin Project.
Canaccord Genuity upgraded its 2026 EBITDA forecast by 17% to reflect the operational outperformance and the new strategic investment, noting the valuation remains attractive.
This report was published on May 3, 2026.
Target price is $1.55 Current Price is $1.42 Difference: $0.13
If MLX meets the Canaccord Genuity target it will return approximately 9% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 15.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.47.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 15.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.47.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NMG NEW MURCHISON GOLD LIMITED
Gold & Silver – Overnight Price: $0.05
Taylor Collison rates ((NMG)) as Speculative Buy (1) –
It was a mixed quarter for New Murchison Gold, Taylor Collison reports, with production of 16.7koz slightly below expectation as higher demand from Westgold ((WGX)) led to lower-grade ore filling spare Bluebird capacity, weighing on head grade that pushed costs higher.
This was offset by a record gold sales price resulting in a $64m quarterly cash build to circa $156m on the balance sheet. The broker expects next quarter production to revert to mine plan, supporting a return to forecasted grade and unit costs.
With no debt, no hedging and a cash balance approaching $190m versus a $530m market cap, Taylor Collison thinks New Murchison looks undervalued versus its peers as it is now a proven producer. Speculative Buy retained, target 6.8c.
This report was published on May 4, 2026.
Target price is $0.07 Current Price is $0.05 Difference: $0.019
If NMG meets the Taylor Collison target it will return approximately 39% (excluding dividends, fees and charges).
The company’s fiscal year ends in September.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
OMA OMEGA OIL & GAS LIMITED
Energy – Overnight Price: $0.82
Canaccord Genuity rates ((OMA)) as Speculative Buy (1) –
Canaccord Genuity maintains its Speculative Buy rating for Omega Oil & Gas but lowers the target price to $1.25 from $1.30 to account for dilution following a recent capital raising.
The broker describes the Taroom Trough as one of Australia’s most promising untapped resources, with pro forma cash of approximately $110m now enabling the company to pursue exploration and appraisal at scale.
During the quarter, the company executed an expanded drilling contract to deploy full-scale, “US-style” horizontal wells featuring larger diameters and 2,000m laterals to demonstrate development-scale flow rates.
Sector headwinds including global energy security concerns and vocal advocacy from the Queensland Premier support this aggressive program.
With civil works for the first vertical well commencing in May 2026, the broker anticipates a highly active year culminating in an updated resource and reserve assessment by late 2026.
This report was published on May 3, 2026.
Target price is $1.25 Current Price is $0.82 Difference: $0.425
If OMA meets the Canaccord Genuity target it will return approximately 52% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMD RESMED INC
Medical Equipment & Devices – Overnight Price: $28.96
Canaccord Genuity rates ((RMD)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for ResMed, lowering the target price to $44.50 from $46.50 following the release of what is assessed as a robust third-quarter result.
Gross margins expanded 290 basis points to 62.2%, benefiting from efficiency programs, improved supply contracts, and favourable freight mixes.
The broker notes broader healthcare sector de-rating and noise surrounding GLP-1 weight loss drugs continue weighing on market sentiment, though these present intrinsically remediable challenges.
The recent US$340m acquisition of Noctrix Health creates a near-term -US2.0c earnings headwind per share, prompting minor downward revisions to near-term forecasts.
Unfavourable currency translation movements primarily drove the reduction in the final valuation.
This report was published on May 3, 2026.
Target price is $44.50 Current Price is $28.96 Difference: $15.54
If RMD meets the Canaccord Genuity target it will return approximately 54% (excluding dividends, fees and charges).
Current consensus price target is $43.21, suggesting upside of 49.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 36.63 cents and EPS of 165.35 cents.
At the last closing share price the estimated dividend yield is 1.26%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.51.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 156.5, implying annual growth of N/A.
Current consensus DPS estimate is 34.5, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 18.5.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 39.17 cents and EPS of 182.99 cents.
At the last closing share price the estimated dividend yield is 1.35%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.83.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 173.0, implying annual growth of 10.5%.
Current consensus DPS estimate is 38.3, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 16.7.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((RMD)) as Overweight (2) –
Jarden maintains an Overweight rating for ResMed while lowering its target price to $42.70 from $44.80 following what is labeled a solid third-quarter result.
The medical device manufacturer delivered 19.7% net profit growth, overcoming a slight -1% revenue miss in US devices through strong rest-of-world sales and robust gross margin expansion driven by production efficiencies.
Management anticipates these productivity gains will offset ongoing inflationary pressures across electronic components and plastics heading into FY27.
The broker trimmed its FY26 earnings per share forecast to US111.8c from US112.4c to account for near-term dilution from the US$340m acquisition of Noctrix Health, an FDA-approved neurostimulation therapy provider for restless leg syndrome.
Jarden views the stock as attractively valued given its double-digit earnings growth profile, ongoing share buybacks, and expanding total addressable market.
This report was published on May 2, 2026.
Target price is $42.70 Current Price is $28.96 Difference: $13.74
If RMD meets the Jarden target it will return approximately 47% (excluding dividends, fees and charges).
Current consensus price target is $43.21, suggesting upside of 49.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 370.76 cents and EPS of 167.14 cents.
At the last closing share price the estimated dividend yield is 12.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 156.5, implying annual growth of N/A.
Current consensus DPS estimate is 34.5, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 18.5.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 417.10 cents and EPS of 189.86 cents.
At the last closing share price the estimated dividend yield is 14.40%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.25.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 173.0, implying annual growth of 10.5%.
Current consensus DPS estimate is 38.3, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 16.7.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMS RAMELIUS RESOURCES LIMITED
Gold & Silver – Overnight Price: $3.39
Canaccord Genuity rates ((RMS)) as Buy (1) –
Canaccord Genuity maintains a Buy rating on Ramelius Resources while trimming the target price to $6.85 from $6.90 following a slightly weaker March quarter production update.
The company produced 38koz of gold, missing the broker’s initial expectations due to a planned mill shutdown and haul road closures stemming from Cyclone Narelle.
Despite these disruptions, the company generated $211m in sales revenue and ended the period with robust liquidity, including $606m in cash and bullion plus a newly expanded $500m undrawn revolver.
The broker notes the company remains on track to hit the midpoint of its FY26 production guidance (185-205koz).
Management has increased its all-in sustaining cost (AISC) estimates to $1,900–$2,050/oz to account for higher diesel costs, increased gold royalties, and the earlier-than-planned commercial declaration of the Dalgaranga operation.
Near-term capital expenditure guidance was reduced due to timing shifts regarding the Mt Magnet plant expansion, pushing some spending into FY27.
This report was published on May 3, 2026.
Target price is $6.85 Current Price is $3.39 Difference: $3.46
If RMS meets the Canaccord Genuity target it will return approximately 102% (excluding dividends, fees and charges).
Current consensus price target is $5.30, suggesting upside of 56.4%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 14.4, implying annual growth of -65.0%.
Current consensus DPS estimate is 4.4, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 23.5.
Forecast for FY27:
Current consensus EPS estimate is 28.3, implying annual growth of 96.5%.
Current consensus DPS estimate is 5.4, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 12.0.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SCG SCENTRE GROUP
REITs – Overnight Price: $3.74
Jarden rates ((SCG)) as Overweight (2) –
Jarden maintains an Overweight rating for Scentre Group and upgrades its target price to $4.00 from $3.92 following the successful outcome of the subordinated notes tender offer.
Approximately 89% of investors accepted the premium offer, triggering the compulsory redemption of the remaining notes at par, which the broker views as a highly positive capital management outcome.
By replacing the hybrid notes with senior debt, Scentre Group achieves a 400 basis point margin saving, generating an estimated $55m in earnings accretion for the upcoming financial year.
While FY26 guidance remains unchanged — suggesting near-term benefits will be spread to cover hedging in subsequent years — Jarden has upgraded its medium-term earnings forecasts by roughly 4%, underpinning confidence in the REIT’s long-term growth trajectory.
This report was published on May 1, 2026.
Target price is $4.00 Current Price is $3.74 Difference: $0.26
If SCG meets the Jarden target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $3.95, suggesting upside of 5.6%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 18.40 cents and EPS of 23.90 cents.
At the last closing share price the estimated dividend yield is 4.92%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.65.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 23.5, implying annual growth of -31.2%.
Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 15.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 18.80 cents and EPS of 24.90 cents.
At the last closing share price the estimated dividend yield is 5.03%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.02.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.3, implying annual growth of 3.4%.
Current consensus DPS estimate is 18.3, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 15.4.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SGLLV RICEGROWERS LIMITED
Food, Beverages & Tobacco – Overnight Price: $12.68
Canaccord Genuity rates ((SGLLV)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Ricegrowers with a steady $18.70 target price following a recent investor strategy day.
The broker views the company’s “2030 Growth Strategy” as highly logical, underpinned by targeted expansions in the US and the Middle East alongside a deeper push into snacking and non-rice categories.
The planned August 2026 launch of the “Protein-plus” range across key US markets screens as a well-differentiated strategy with significant retailer support.
While the broker anticipates a -$10m pre-tax headwind in FY27 due to dry conditions in the NSW Riverina, current modelling still calls for a 6% net profit compound annual growth rate through FY28.
No changes to near-term earnings forecasts were made, with the broker noting FY26 guidance remains intact ahead of full-year results due in late June.
This report was published on May 4, 2026.
Target price is $18.70 Current Price is $12.68 Difference: $6.02
If SGLLV meets the Canaccord Genuity target it will return approximately 47% (excluding dividends, fees and charges).
The company’s fiscal year ends in April.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 55.00 cents and EPS of 106.00 cents.
At the last closing share price the estimated dividend yield is 4.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.96.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 55.00 cents and EPS of 112.40 cents.
At the last closing share price the estimated dividend yield is 4.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.28.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SKC SKYCITY ENTERTAINMENT GROUP LIMITED
Gaming – Overnight Price: $0.53
Jarden rates ((SKC)) as Overweight (2) –
Jarden maintains an Overweight rating for SkyCity Entertainment but lowers its target price to NZ$0.90 from NZ$1.00 following an earnings downgrade driven by macroeconomic headwinds.
Management has cut FY26 underlying EBITDA guidance by roughly -5% to NZ$180-190m, citing a sharp deterioration in discretionary consumer spending and weak confidence metrics affecting visitation across its Auckland and Adelaide properties.
To offset top-line pressures, the company has initiated further cost-saving measures and entered a non-binding agreement to sell its Albert Street office tower in Auckland.
The broker has revised its near-term earnings models downward, reducing FY26 and FY27 EPS forecasts by -31% and -20%, respectively.
Jarden sees valuation support at current levels, noting structural upside potential from the newly opened NZICC and upcoming regulated online casino operations.
This report was published on May 1, 2026.
Current Price is $0.53. Target price not assessed.
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.55 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.62.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.95 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.29.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
STM SUNSTONE METALS LIMITED
Copper – Overnight Price: $0.36
Shaw and Partners rates ((STM)) as Buy (1) –
Shaw and Partners maintains a Buy rating and $2.10 target price for Sunstone Metals following the release of a highly anticipated scoping study for the Bramaderos gold-copper project in Ecuador.
The study delivered a post-tax net present value of US$0.9bn and a 28% internal rate of return over a 34-month payback period, assuming a base-case gold price of US$3,500/oz.
Drilling across the Copete-Porotillo complex continues to return strong surface grades extending to depth, highlighting the substantial growth potential of the existing 3.6m ounce gold equivalent resource.
Commentary notes the current macroeconomic environment provides a perfect backdrop for concluding a strategic partnership, characterised by elevated regional merger and acquisition activity alongside record-high gold prices.
The broker believes the Ecuadorian assets represent a world-class tier one production hub, leaving the stock significantly undervalued relative to base metal exploration peers.
This report was published on May 4, 2026.
Target price is $2.10 Current Price is $0.36 Difference: $1.735
If STM meets the Shaw and Partners target it will return approximately 475% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 30.42.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 40.56.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TEA TASMEA LIMITED
Mining Sector Contracting – Overnight Price: $5.47
Canaccord Genuity rates ((TEA)) as Initiation of coverage with Buy (1) –
Canaccord Genuity initiates coverage on Tasmea with a Buy rating and a $6.29 target price, highlighting the company’s position as a leading provider of essential maintenance and specialised project services for the Australian resources and infrastructure sectors.
The broker notes a supportive medium-term demand outlook driven by an ageing asset base in the Pilbara region, where a significant portion of installed infrastructure is now 10 to 200-plus years old.
The strategic acquisition of WorkPac in November 2025 is viewed as a major competitive advantage, de-risking workforce availability amid a structural shortage of skilled labour.
Management expects this integration to improve win rates on new contracts and support stronger margins by reducing reliance on external sub-contractors.
With a high-confidence revenue pipeline and strong organic growth levers, the broker anticipates a robust 28% three-year forward underlying EBIT CAGR.
This report was published on May 3, 2026.
Target price is $6.29 Current Price is $5.47 Difference: $0.82
If TEA meets the Canaccord Genuity target it will return approximately 15% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $15.60
Canaccord Genuity rates ((TLX)) as Buy (1) –
Canaccord Genuity reiterates a Buy rating for Telix Pharmaceuticals with an unchanged $30.00 target price following a pipeline update on its novel radioligand therapy, TLX597.
The report highlights the therapy’s favourable dosimetry profile, which demonstrates -55% lower renal uptake and -77% lower lacrimal uptake compared to competing agents like Pluvicto.
Early data show tumour take-up in bony and visceral lesions more than doubled, increasing 173% and 128% respectively.
Current phase 2 trials aim to position the candidate within the material and under-contested metastatic hormone-sensitive prostate cancer market.
Commentary suggests the targeting moiety could be explored with alpha emitters to further ameliorate known toxicities.
This report was published on May 3, 2026.
Target price is $30.00 Current Price is $15.60 Difference: $14.4
If TLX meets the Canaccord Genuity target it will return approximately 92% (excluding dividends, fees and charges).
Current consensus price target is $25.84, suggesting upside of 65.6%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -1.8, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.5, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 41.6.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
WGX WESTGOLD RESOURCES LIMITED
Gold & Silver – Overnight Price: $5.45
Canaccord Genuity rates ((WGX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Westgold Resources while lowering the target price to $9.70 from $9.80 following the March quarter results.
Group production reached 93koz, consistent with the broker’s expectations, though all-in sustaining costs (AISC) of $3,338/oz were higher than forecast due to operational challenges at the Southern Goldfields.
Murchison operations delivered an outperformance driven by Westgold’s Ore Purchase Agreement (OPA) and increased mining rates at Bluebird, which is nearing its 1Mtpa target.
Conversely, the Beta Hunt mine missed production targets due to ventilation fan failures and lower-than-expected grades.
The report highlights the company maintained its FY26 guidance and continues its on-market share buy-back program, supported by a strong liquidity position of approximately $1.5bn.
This report was published on May 3, 2026.
Target price is $9.70 Current Price is $5.45 Difference: $4.25
If WGX meets the Canaccord Genuity target it will return approximately 78% (excluding dividends, fees and charges).
Current consensus price target is $8.65, suggesting upside of 58.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 64.7, implying annual growth of 1580.5%.
Current consensus DPS estimate is 5.8, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 8.4.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 98.1, implying annual growth of 51.6%.
Current consensus DPS estimate is 15.4, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 5.6.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: 29M - 29METALS LIMITED
For more info SHARE ANALYSIS: A11 - ATLANTIC LITHIUM LIMITED.
For more info SHARE ANALYSIS: ANZ - ANZ GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: AR1 - AUSTRAL RESOURCES AUSTRALIA LIMITED
For more info SHARE ANALYSIS: ARX - AROA BIOSURGERY LIMITED
For more info SHARE ANALYSIS: AWJ - AURIC MINING LIMITED
For more info SHARE ANALYSIS: BET - BETMAKERS TECHNOLOGY GROUP LIMITED
For more info SHARE ANALYSIS: BGL - BELLEVUE GOLD LIMITED
For more info SHARE ANALYSIS: BMN - BANNERMAN ENERGY LIMITED
For more info SHARE ANALYSIS: BOT - BOTANIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: BUB - BUBS AUSTRALIA LIMITED
For more info SHARE ANALYSIS: CMA - CARMA LIMITED
For more info SHARE ANALYSIS: CMM - CAPRICORN METALS LIMITED
For more info SHARE ANALYSIS: COL - COLES GROUP LIMITED
For more info SHARE ANALYSIS: CYG - COVENTRY GROUP LIMITED
For more info SHARE ANALYSIS: CYL - CATALYST METALS LIMITED
For more info SHARE ANALYSIS: DUG - DUG TECHNOLOGY LIMITED
For more info SHARE ANALYSIS: ELV - ELEVRA LITHIUM LIMITED
For more info SHARE ANALYSIS: FLT - FLIGHT CENTRE TRAVEL GROUP LIMITED
For more info SHARE ANALYSIS: GEM - G8 EDUCATION LIMITED
For more info SHARE ANALYSIS: GNC - GRAINCORP LIMITED
For more info SHARE ANALYSIS: HPG - HIPAGES GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: KCN - KINGSGATE CONSOLIDATED LIMITED
For more info SHARE ANALYSIS: LMG - LATROBE MAGNESIUM LIMITED
For more info SHARE ANALYSIS: LTR - LIONTOWN LIMITED
For more info SHARE ANALYSIS: MLX - METALS X LIMITED
For more info SHARE ANALYSIS: NMG - NEW MURCHISON GOLD LIMITED
For more info SHARE ANALYSIS: OMA - OMEGA OIL & GAS LIMITED
For more info SHARE ANALYSIS: RMD - RESMED INC
For more info SHARE ANALYSIS: RMS - RAMELIUS RESOURCES LIMITED
For more info SHARE ANALYSIS: SCG - SCENTRE GROUP
For more info SHARE ANALYSIS: SKC - SKYCITY ENTERTAINMENT GROUP LIMITED
For more info SHARE ANALYSIS: SRZ - STELLAR RESOURCES LIMITED
For more info SHARE ANALYSIS: STM - SUNSTONE METALS LIMITED
For more info SHARE ANALYSIS: TEA - TASMEA LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: WGX - WESTGOLD RESOURCES LIMITED
For more info SHARE ANALYSIS: WOW - WOOLWORTHS GROUP LIMITED